Erschienen in:

01.03.2023 | REVIEW ARTICLE

Purinergic P2X7R as a potential target for pancreatic cancer

verfasst von: Qingqing Yu, Xin Wang, Xinyu Li, Xue Bai, Ronglan Zhao, Xiaoxiang Peng

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2023

Abstract

Pancreatic cancer is one of the deadliest types of cancer, with a death rate nearly equal to the incidence. The P2X7 receptor (P2X7R) is a kind of extracellular adenosine triphosphate (ATP)-gated ion channel with special permeability, which exists in most tissues of human body and mediates inflammation-related signaling pathways and immune signal transduction after activation. P2X7R is also present on the surface of several tumor cells and is involved in tumor growth and progression. P2X7R expression in pancreatic cancer has also been identified in recent studies. Activation of P2X7R in pancreatic cancer can support the proliferation of pancreatic stellate cells, participate in protein interactions, and mediate ERK1/2, IL-6/STAT3, hCAP-18/LL-37, PI3K/AKT signaling pathways to promote pancreatic cancer progression. Inhibitors targeting P2X7R can inhibit the development of pancreatic cancer and are expected to be used in clinical therapy. Therefore, P2X7R is promising as a potential therapeutic target for pancreatic cancer. This article reviews the progress of research on P2X7R in pancreatic cancer.

Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694–705. https://doi.org/10.3748/wjg.v22.i44.9694.CrossRefPubMedPubMedCentral

Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851–62. https://doi.org/10.1001/jama.2021.13027.CrossRefPubMedPubMedCentral

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008–20. https://doi.org/10.1016/S0140-6736(20)30974-0.CrossRefPubMed

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20. https://doi.org/10.1016/S0140-6736(10)62307-0.CrossRefPubMedPubMedCentral

Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004;240:31–304. https://doi.org/10.1016/s0074-7696(04)40002-3.CrossRefPubMed

Cai X, Yao Y, Teng F, Li Y, Wu L, Yan W, et al. The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity. Int Immunopharmacol. 2021;101:108297. https://doi.org/10.1016/j.intimp.2021.108297.CrossRefPubMed

Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, Di Virgilio F, et al. P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol. 2020;11:793. https://doi.org/10.3389/fphar.2020.00793.CrossRefPubMedPubMedCentral

Aria H, Rezaei M, Nazem S, Daraei A, Nikfar G, Mansoori B, et al. Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: the prime suspect in cancer therapeutic resistance. Front Immunol. 2022;13:947885. https://doi.org/10.3389/fimmu.2022.947885.CrossRefPubMedPubMedCentral

Notomi S, Hisatomi T, Kanemaru T, Takeda A, Ikeda Y, Enaida H, et al. Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death. Am J Pathol. 2011;179:2798–809. https://doi.org/10.1016/j.ajpath.2011.08.035.CrossRefPubMedPubMedCentral

10.

Roger S, Pelegrin P. P2X7 receptor antagonism in the treatment of cancers. Expert Opin Investig Drugs. 2011;20:875–80. https://doi.org/10.1517/13543784.2011.583918.CrossRefPubMed

11.

Novak I, Yu H, Magni L, Deshar G. Purinergic signaling in pancreas-from physiology to therapeutic strategies in pancreatic cancer. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21228781.CrossRefPubMedPubMedCentral

12.

Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 Receptor in Infection and Inflammation. Immunity. 2017;47:15–31. https://doi.org/10.1016/j.immuni.2017.06.020.CrossRefPubMed

13.

Giannuzzo A, Pedersen SF, Novak I. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer. 2015;14:203. https://doi.org/10.1186/s12943-015-0472-4.CrossRefPubMedPubMedCentral

14.

Pothula SP, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression. Pancreatology. 2020;20:409–18. https://doi.org/10.1016/j.pan.2020.01.003.CrossRefPubMed

15.

Magni L, Bouazzi R, Heredero Olmedilla H, Petersen PSS, Tozzi M, Novak I. The P2X7 receptor stimulates IL-6 release from pancreatic stellate cells and tocilizumab prevents activation of STAT3 in pancreatic cancer cells. Cells. 2021. https://doi.org/10.3390/cells10081928.CrossRefPubMedPubMedCentral

16.

Choi JH, Ji YG, Ko JJ, Cho HJ, Lee DH. Activating P2X7 Receptors Increases Proliferation of Human Pancreatic Cancer Cells via ERK1/2 and JNK. Pancreas. 2018;47:643–51. https://doi.org/10.1097/MPA.0000000000001055.CrossRefPubMed

17.

Sainz B Jr, Alcala S, Garcia E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut. 2015;64:1921–35. https://doi.org/10.1136/gutjnl-2014-308935.CrossRefPubMed

18.

Campos-Contreras ADR, Diaz-Munoz M, Vazquez-Cuevas FG. Purinergic signaling in the hallmarks of cancer. Cells. 2020. https://doi.org/10.3390/cells9071612.CrossRefPubMedPubMedCentral

19.

von Muecke-Heim IA, Ries C, Urbina L, Deussing JM. P2X7R antagonists in chronic stress-based depression models: a review. Eur Arch Psychiatry Clin Neurosci. 2021;271:1343–58. https://doi.org/10.1007/s00406-021-01306-3.CrossRef

20.

Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346–58. https://doi.org/10.1038/onc.2010.292.CrossRefPubMed

21.

Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, et al. Nucleotides acting at P2Y receptors: connecting structure and function. Mol Pharmacol. 2015;88:220–30. https://doi.org/10.1124/mol.114.095711.CrossRefPubMedPubMedCentral

22.

Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014;66:638–75. https://doi.org/10.1124/pr.113.008003.CrossRefPubMed

23.

Di Virgilio F, Schmalzing G, Markwardt F. The elusive P2X7 macropore. Trends Cell Biol. 2018;28:392–404. https://doi.org/10.1016/j.tcb.2018.01.005.CrossRefPubMed

24.

Di Virgilio F, Jiang LH, Roger S, Falzoni S, Sarti AC, Vultaggio-Poma V, et al. Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol. 2019;629:115–50. https://doi.org/10.1016/bs.mie.2019.07.043.CrossRefPubMed

25.

De Salis SKF, Li L, Chen Z, Lam KW, Skarratt KK, Balle T, et al. Alternatively spliced isoforms of the P2X7 receptor: structure, function and disease associations. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23158174.CrossRefPubMedPubMedCentral

26.

Denlinger LC, Fisette PL, Sommer JA, Watters JJ, Prabhu U, Dubyak GR, et al. Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol (Baltimore Md: 1950). 2001;167(2001):1871–6. https://doi.org/10.4049/jimmunol.167.4.1871.CrossRef

27.

Cunha SR, Mohler PJ. Ankyrin protein networks in membrane formation and stabilization. J Cell Mol Med. 2009;13:4364–76. https://doi.org/10.1111/j.1582-4934.2009.00943.x.CrossRefPubMedPubMedCentral

28.

Smart ML, Gu B, Panchal RG, Wiley J, Cromer B, Williams DA, et al. P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem. 2003;278:8853–60. https://doi.org/10.1074/jbc.M211094200.CrossRefPubMed

29.

Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (New York, NY.). 1996;272:735–8. https://doi.org/10.1126/science.272.5262.735.CrossRef

30.

Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387–96. https://doi.org/10.1016/s1074-7613(00)80252-6.CrossRefPubMed

31.

Wittmann I, Schönefeld M, Aichele D, Groer G, Gessner A, Schnare M. Murine bactericidal/permeability-increasing protein inhibits the endotoxic activity of lipopolysaccharide and gram-negative bacteria. J Immunol (Baltimore Md: 1950). 2008;180(2008):7546–52. https://doi.org/10.4049/jimmunol.180.11.7546.CrossRef

32.

Roger S, Jelassi B, Couillin I, Pelegrin P, Besson P, Jiang LH. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochim Biophys Acta. 2015;1848:2584–602. https://doi.org/10.1016/j.bbamem.2014.10.029.CrossRefPubMed

33.

Illes P, Muller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, et al. Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol. 2021;178:489–514. https://doi.org/10.1111/bph.15299.CrossRefPubMed

34.

Gu BJ, Saunders BM, Jursik C, Wiley JS. The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood. 2010;115:1621–31. https://doi.org/10.1182/blood-2009-11-251744.CrossRefPubMed

35.

Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006;25:5071–82. https://doi.org/10.1038/sj.emboj.7601378.CrossRefPubMedPubMedCentral

36.

Ugur M, Ugur O. A mechanism-based approach to P2X7 receptor action. Mol Pharmacol. 2019;95:442–50. https://doi.org/10.1124/mol.118.115022.CrossRefPubMed

37.

Kopp R, Krautloher A, Ramirez-Fernandez A, Nicke A. P2X7 interactions and signaling—making head or tail of it. Front Mol Neurosci. 2019;12:183. https://doi.org/10.3389/fnmol.2019.00183.CrossRefPubMedPubMedCentral

38.

Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F. The P2X7 receptor: a main player in inflammation. Biochem Pharmacol. 2018;151:234–44. https://doi.org/10.1016/j.bcp.2017.12.021.CrossRefPubMed

39.

Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, et al. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012;72:2957–69. https://doi.org/10.1158/0008-5472.CAN-11-1947.CrossRefPubMed

40.

Grassi F, De Ponte Conti B. The P2X7 receptor in tumor immunity. Front Cell Dev Biol. 2021;9:694831. https://doi.org/10.3389/fcell.2021.694831.CrossRefPubMedPubMedCentral

41.

Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2018;18:601–18. https://doi.org/10.1038/s41568-018-0037-0.CrossRefPubMed

42.

Park M, Kim J, Phuong NTT, Park JG, Park JH, Kim YC, et al. Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Sci Rep. 2019;9:11587. https://doi.org/10.1038/s41598-019-47734-z.CrossRefPubMedPubMedCentral

43.

Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, et al. Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology. 2008;149:389–96. https://doi.org/10.1210/en.2007-1223.CrossRefPubMed

44.

Vazquez-Cuevas FG, Martinez-Ramirez AS, Robles-Martinez L, Garay E, Garcia-Carranca A, Perez-Montiel D, et al. Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J Cell Biochem. 2014;115:1955–66. https://doi.org/10.1002/jcb.24867.CrossRefPubMed

45.

Zhang Y, Ding J, Wang L. The role of P2X7 receptor in prognosis and metastasis of colorectal cancer. Adv Med Sci. 2019;64:388–94. https://doi.org/10.1016/j.advms.2019.05.002.CrossRefPubMed

46.

Boldrini L, Giordano M, Alì G, Servadio A, Pelliccioni S, Niccoli C, et al. P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). J Negat Results Biomed. 2014;13:16. https://doi.org/10.1186/1477-5751-13-16.CrossRefPubMedPubMedCentral

47.

Pegoraro A, Adinolfi E. The ATP/P2X7 axis is a crucial regulator of leukemic initiating cells proliferation and homing and an emerging therapeutic target in acute myeloid leukemia. Purinergic Signal. 2021;17:319–21. https://doi.org/10.1007/s11302-021-09789-4.CrossRefPubMedPubMedCentral

48.

Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, et al. P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis. 2021;12:1088. https://doi.org/10.1038/s41419-021-04378-0.CrossRefPubMedPubMedCentral

49.

Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology. 2004;44:206–15. https://doi.org/10.1111/j.0309-0167.2004.01798.x.CrossRefPubMed

50.

Sun SH. Roles of P2X7 receptor in glial and neuroblastoma cells: the therapeutic potential of P2X7 receptor antagonists. Mol Neurobiol. 2010;41:351–5. https://doi.org/10.1007/s12035-010-8120-x.CrossRefPubMed

51.

Liu H, Liu W, Liu Z, Liu Y, Zhang W, Xu L, et al. Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection. Tumour Biol. 2015;36:5039–49. https://doi.org/10.1007/s13277-015-3155-2.CrossRefPubMed

52.

Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI. The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:1906–13. https://doi.org/10.1158/1055-9965.EPI-06-0407.CrossRefPubMedPubMedCentral

53.

Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, et al. Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol. 2007;106:233–43. https://doi.org/10.1016/j.ygyno.2007.03.032.CrossRefPubMedPubMedCentral

54.

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6. https://doi.org/10.1242/jcs.116392.CrossRefPubMed

55.

Burnstock G, Knight GE. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 2018;14:1–18. https://doi.org/10.1007/s11302-017-9593-0.CrossRefPubMed

56.

Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005;16:3260–72. https://doi.org/10.1091/mbc.e04-11-1025.CrossRefPubMedPubMedCentral

57.

de Andrade Mello P, Bian S, Savio LEB, Zhang H, Zhang J, Junger W, et al. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death. Oncotarget. 2017;8:67254–68. https://doi.org/10.18632/oncotarget.18595.CrossRefPubMedPubMedCentral

58.

Feng YH, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006;281:17228–37. https://doi.org/10.1074/jbc.M602999200.CrossRefPubMed

59.

Pegoraro A, De Marchi E, Adinolfi E. P2X7 variants in oncogenesis. Cells. 2021. https://doi.org/10.3390/cells10010189.CrossRefPubMedPubMedCentral

60.

Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F, et al. Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS ONE. 2014;9:e107224. https://doi.org/10.1371/journal.pone.0107224.CrossRefPubMedPubMedCentral

61.

Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, et al. A phase I clinical trial demonstrates that nfP2X(7) -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017;177:117–24. https://doi.org/10.1111/bjd.15364.CrossRefPubMed

62.

Qiao C, Tang Y, Li Q, Zhu X, Peng X, Zhao R. ATP-gated P2X7 receptor as a potential target for prostate cancer. Hum Cell. 2022;35:1346–54. https://doi.org/10.1007/s13577-022-00729-x.CrossRefPubMed

63.

Qian F, Xiao J, Hu B, Sun N, Yin W, Zhu J. High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum Pathol. 2017;64:61–8. https://doi.org/10.1016/j.humpath.2017.03.019.CrossRefPubMed

64.

Zhang Y, Cheng H, Li W, Wu H, Yang Y. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3beta/beta-catenin and mTOR/HIF1alpha/VEGF signaling. Int J Cancer. 2019;145:1068–82. https://doi.org/10.1002/ijc.32207.CrossRefPubMedPubMedCentral

65.

Tan C, Han LI, Zou L, Luo C, Liu A, Sheng X, et al. Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells. Exp Ther Med. 2015;10:1472–8. https://doi.org/10.3892/etm.2015.2705.CrossRefPubMedPubMedCentral

66.

Qin J, Zhang X, Tan B, Zhang S, Yin C, Xue Q, et al. Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res. 2020;8:1426–39. https://doi.org/10.1158/2326-6066.CIR-20-0123.CrossRefPubMed

67.

Ghalali A, Wiklund F, Zheng H, Stenius U, Hogberg J. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis. 2014;35:1547–55. https://doi.org/10.1093/carcin/bgu019.CrossRefPubMed

68.

Zhang Y, Li F, Wang L, Lou Y. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor. Biochem Biophys Res Commun. 2021;558:147–53. https://doi.org/10.1016/j.bbrc.2021.04.076.CrossRefPubMed

69.

de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol. 2017;8:1526. https://doi.org/10.3389/fimmu.2017.01526.CrossRefPubMedPubMedCentral

70.

He X, Wan J, Yang X, Zhang X, Huang D, Li X, et al. Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models. J Clin Invest. 2021. https://doi.org/10.1172/JCI140242.CrossRefPubMedPubMedCentral

71.

Künzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol. 2007;292:G223–230. https://doi.org/10.1152/ajpgi.00259.2006.CrossRefPubMed

72.

Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, et al. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget. 2017;8:97822–34. https://doi.org/10.18632/oncotarget.22085.CrossRefPubMedPubMedCentral

73.

Zhang GX, Wang MX, Nie W, Liu DW, Zhang Y, Liu HB. P2X7R blockade prevents NLRP3 inflammasome activation and pancreatic fibrosis in a mouse model of chronic pancreatitis. Pancreas. 2017;46:1327–35. https://doi.org/10.1097/MPA.0000000000000928.CrossRefPubMed

74.

Apte M, Pirola RC, Wilson JS. Pancreatic stellate cell: physiologic role, role in fibrosis and cancer. Curr Opin Gastroenterol. 2015;31:416–23. https://doi.org/10.1097/MOG.0000000000000196.CrossRefPubMed

75.

Masamune A, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol. 2009;7:S48-54. https://doi.org/10.1016/j.cgh.2009.07.038.CrossRefPubMed

76.

Künzli BM, Nuhn P, Enjyoji K, Banz Y, Smith RN, Csizmadia E, et al. Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology. 2008;134:292–305. https://doi.org/10.1053/j.gastro.2007.10.030.CrossRefPubMed

77.

Haanes KA, Schwab A, Novak I. The P2X7 receptor supports both life and death in fibrogenic pancreatic stellate cells. PLoS ONE. 2012;7:e51164. https://doi.org/10.1371/journal.pone.0051164.CrossRefPubMedPubMedCentral

78.

Fallah G, Romer T, Detro-Dassen S, Braam U, Markwardt F, Schmalzing G. TMEM16A(a)/anoctamin-1 shares a homodimeric architecture with CLC chloride channels. Mol Cell Proteomics. 2011;10:M110 004697. https://doi.org/10.1074/mcp.M110.004697.CrossRefPubMed

79.

Stolz M, Klapperstuck M, Kendzierski T, Detro-Dassen S, Panning A, Schmalzing G, et al. Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors. Pflugers Arch. 2015;467:2121–40. https://doi.org/10.1007/s00424-015-1687-3.CrossRefPubMed

80.

Mazzone A, Eisenman ST, Strege PR, Yao Z, Ordog T, Gibbons SJ, et al. Inhibition of cell proliferation by a selective inhibitor of the Ca(2+)-activated Cl(-) channel, Ano1. Biochem Biophys Res Commun. 2012;427:248–53. https://doi.org/10.1016/j.bbrc.2012.09.022.CrossRefPubMedPubMedCentral

81.

Wang B, Zhu XX, Pan LY, Chen HF, Shen XY. PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway. Pathol Res Pract. 2020;216:152910. https://doi.org/10.1016/j.prp.2020.152910.CrossRefPubMed

82.

Zhang Q, Li T, Wang Z, Kuang X, Shao N, Lin Y. lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway. J Cell Mol Med. 2020;24:8236–47. https://doi.org/10.1111/jcmm.15499.CrossRefPubMedPubMedCentral

83.

Jin C, Chen Z, Shi W, Lian Q. Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway. Oncol Rep. 2019;41:3060–8. https://doi.org/10.3892/or.2019.7052.CrossRefPubMed

84.

Yan Z, Ohuchida K, Fei S, Zheng B, Guan W, Feng H, et al. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res. 2019;38:221. https://doi.org/10.1186/s13046-019-1226-8.CrossRefPubMedPubMedCentral

85.

Tan G, Huang C, Chen J, Zhi F. HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway. J Hematol Oncol. 2020;13:149. https://doi.org/10.1186/s13045-020-00985-0.CrossRefPubMedPubMedCentral

86.

Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204. https://doi.org/10.1016/j.ctrv.2003.07.007.CrossRefPubMed

87.

Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 2011;105:329–36. https://doi.org/10.1038/bjc.2011.241.CrossRefPubMedPubMedCentral

88.

Mistafa O, Stenius U. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol. 2009;78:1115–26. https://doi.org/10.1016/j.bcp.2009.06.016.CrossRefPubMed

89.

Giannuzzo A, Saccomano M, Napp J, Ellegaard M, Alves F, Novak I. Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int J Cancer. 2016;139:2540–52. https://doi.org/10.1002/ijc.30380.CrossRefPubMedPubMedCentral

90.

Sperb N, Tsesmelis M, Wirth T. Crosstalk between tumor and stromal cells in pancreatic ductal adenocarcinoma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155486.CrossRefPubMedPubMedCentral

91.

Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer. 2012;131:1951–62. https://doi.org/10.1002/ijc.27456.CrossRefPubMedPubMedCentral

92.

Dong X, Fu J, Yin X, Cao S, Li X, Lin L, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 2016;30:1207–18. https://doi.org/10.1002/ptr.5631.CrossRefPubMedPubMedCentral

93.

Liu L, Zou J, Liu X, Jiang LH, Li J. Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor. Eur J Pharmacol. 2010;640:15–9. https://doi.org/10.1016/j.ejphar.2010.04.036.CrossRefPubMed

94.

Zhu T, Zhang L, Ling S, Duan J, Qian F, Li Y, et al. Scropolioside B inhibits IL-1beta and cytokines expression through NF-kappaB and inflammasome NLRP3 pathways. Mediators Inflamm. 2014. https://doi.org/10.1155/2014/819053.CrossRefPubMedPubMedCentral

95.

Rodgers MA, Bowman JW, Fujita H, Orazio N, Shi M, Liang Q, et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J Exp Med. 2014;211:1333–47. https://doi.org/10.1084/jem.20132486.CrossRefPubMedPubMedCentral

96.

Zhang Q, Hu F, Guo F, Zhou Q, Xiang H, Shang D. Emodin attenuates adenosine triphosphate-induced pancreatic ductal cell injury in vitro via the inhibition of the P2X7/NLRP3 signaling pathway. Oncol Rep. 2019;42:1589–97. https://doi.org/10.3892/or.2019.7270.CrossRefPubMed

97.

Zhang Q, Tao X, Xia S, Qu J, Song H, Liu J, et al. Emodin attenuated severe acute pancreatitis via the P2X ligand-gated ion channel 7/NOD-like receptor protein 3 signaling pathway. Oncol Rep. 2019;41:270–8. https://doi.org/10.3892/or.2018.6844.CrossRefPubMed

Titel: Purinergic P2X7R as a potential target for pancreatic cancer
verfasst von: Qingqing Yu
Xin Wang
Xinyu Li
Xue Bai
Ronglan Zhao
Xiaoxiang Peng
Publikationsdatum: 01.03.2023
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03123-7

Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer

RESEARCH ARTICLE

Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia

RESEARCH ARTICLE

Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity

REVIEW ARTICLE

The role of lipid metabolism in cancer radioresistance

REVIEW ARTICLE

Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines

RESEARCH ARTICLE

Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study

Open Access
RESEARCH ARTICLE

Neu im Fachgebiet Onkologie

Alternde Blutbildung lässt solide Tumoren wachsen

29.04.2025
Solide Tumoren
Nachrichten

Bestimmte mutierte Blutzellen erhöhen nicht nur das Risiko für hämatologische Neoplasien, sondern sind offenbar auch bei soliden Tumoren prognostisch ungünstig. Dafür sprechen aktuelle Erkenntnisse, insbesondere beim nichtkleinzelligen Lungenkarzinom.

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA (ctDNA) könnte auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Ringen um den richtigen Umgang mit Zufallsbefunden

24.04.2025
DGP 2025
Kongressbericht

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Purinergic P2X7R as a potential target for pancreatic cancer

Abstract

Weitere Artikel der Ausgabe 8/2023

Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer

Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia

Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity

The role of lipid metabolism in cancer radioresistance

Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines

Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study

Neu im Fachgebiet Onkologie

Alternde Blutbildung lässt solide Tumoren wachsen

ctDNA erkennt minimale Resterkrankung beim Melanom

Höhere Dosis von Dexamethason senkt Überlebenschancen

Ringen um den richtigen Umgang mit Zufallsbefunden

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten